SWOT Analysis
- S
- W
- O
- T
-
Strength (9)
Strong Momentum: Price above short, medium and long term moving averages
-
Weakness (5)
See all stocks where promoters decreased their stake. Promoters decreasing their shareholding in a stock is considered negative for the stock.
-
Opportunity (0)
-
Threats (0)
- Strong Momentum: Price above short, medium and long term moving averages
- Efficient in managing Assets to generate Profits - ROA improving since last 2 year
- Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
- Companies with Low Debt
- Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
- Annual Net Profits improving for last 2 years
- Companies with Zero Promoter Pledge
- Highest Recovery from 52 Week Low
- RSI indicating price strength
Technical Analysis
Moving Averages
- 5 Day 1,573.6
- 10 Day 1,569.2
- 12 Day 1,564.6
- 20 Day 1,539.2
- 26 Day 1,518.2
- 50 Day 1,441.0
- 100 Day 1,321.3
- 200 Day 1,173.0
Current Price
- Bullish Moving Averages 16
- Bearish Moving Averages 0
Resistance and support
- First Resistance 1,626.2
- Second Resistance 1,651.8
- Third Resistance 1,689.8
- First Support 1,562.6
- Second Support 1,524.6
- Third Support 1,499.0
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
- CAGR IN 10 YEARS
- 13.39%
- 16.28%
- 18.72%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 2,153.23 | 1,642.05 | 1,418.68 | 1,157.40 | 841.02 |
|
| Operating Profit | 593.42 | 392.35 | 288.04 | 166.88 | 124.88 |
|
| OP Profit Margin | 27.56 | 23.89 | 20.30 | 14.42 | 14.85 |
|
| Interest | 34.08 | 71.94 | 81.15 | 74.38 | 50.98 |
|
| Profit After Tax | 341.48 | 173.46 | 95.23 | 24.24 | 15.68 |
|
| Cash Profit | 468.55 | 331.77 | 211.13 | 113.16 | 95.39 |
|
| EPS | 16.12 | 8.32 | 53.92 | 13.76 | 8.93 |
|
- CAGR IN 10 YEARS
- 14.95%
- -1.26%
- 19.41%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Equity | 21.18 | 20.84 | 18.05 | 18.01 | 17.94 |
|
| Reserve Surplus | 2,486.79 | 2,146.58 | 993.15 | 894.72 | 873.42 |
|
| TOT Debts | 223.19 | 287.18 | 867.61 | 868.82 | 751.32 |
|
| Gross Block | 2,412.86 | 1,944.31 | 1,525.89 | 1,269.53 | 883.62 |
|
| Capital Work In Progress | 270.45 | 124.46 | 106.90 | 151.00 | 345.16 |
|
| Cash Liquid Investment | 107.56 | 457.96 | 152.00 | 80.02 | 123.53 |
|
| Net Working Capital | 512.79 | 835.93 | 610.46 | 623.27 | 627.97 |
|
| Current Assets | 1,409.46 | 1,546.23 | 1,002.28 | 1,006.34 | 943.66 |
|
| Current Liabilities | 896.68 | 710.30 | 391.83 | 383.07 | 315.69 |
|
Jun 2026 (CR) |
Mar 2026 (CR) |
Dec 2025 (CR) |
Sep 2025 (CR) |
Jun 2025 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 546.73 | 594.34 | 549.18 | 526.67 | 483.04 |
|
| Gross Profit | 137.46 | 178.02 | 171.07 | 147.08 | 112.31 |
|
| Gross Profit Margins | 67.89 | 73.34 | 79.47 | 73.08 | 67.84 |
|
| Operating Profit | 139.91 | 168.14 | 170.68 | 139.85 | 112.99 |
|
| OP Profit Margin | 18.53 | 24.06 | 25.22 | 22.51 | 18.36 |
|
| Interest | 5.98 | 6.16 | 8.06 | 7.70 | 10.70 |
|
| Profit After Tax | 71.34 | 102.53 | 97.63 | 82.95 | 58.37 |
|
| Cash Profit | 113.47 | 143.69 | 138.23 | 119.16 | 92.70 |
|
| EPS | 3.36 | 4.85 | 4.64 | 3.97 | 2.80 |
|
- CAGR IN 10 YEARS
- 14.95%
- -1.26%
- 19.41%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| PE | 60.19 | 91.57 | 0.00 | 0.00 | 0.00 |
|
| P/BV | 8.20 | 7.33 | 0.00 | 0.00 | 0.00 |
|
| MCAP Sales | 9.55 | 9.67 | 0.00 | 0.00 | 0.00 |
|
| Asset Turnover | 0.82 | 0.75 | 0.77 | 0.64 | 0.50 |
|
| EV/EBITDA | 32.17 | 36.57 | 0.00 | 0.00 | 0.00 |
|
| DEBT/EQUITY | 0.11 | 0.36 | 0.90 | 0.90 | 0.79 |
|
| ROE | 14.61 | 10.92 | 9.90 | 2.69 | 0.50 |
|
| ROCE | 18.71 | 13.87 | 11.36 | 5.96 | 3.72 |
|
Quick Results Snapshot
Q1FY27 Quarterly Result Announced for Sai Life Science Ltd.
Pharmaceuticals company Sai Life Science announced Q1FY27 results
Consolidated Financial Highlights:
- Revenue from Operations: The company reported revenue of Rs 5,542.85 million in Q1FY27, representing a YoY increase of 11.66% from Rs 4,964.19 million in Q1FY26 and a QoQ decrease of 7.95% from Rs 6,021.39 million in Q4FY26.
- Total Income: Total income for Q1FY27 stood at Rs 5,578.28 million, an increase of 10.17% YoY compared to Rs 5,063.23 million in Q1FY26 and a decrease of 9.69% QoQ compared to Rs 6,176.58 million in Q4FY26.
- Profit Before Tax: The PBT reached Rs 979.74 million in Q1FY27, growing by 21.33% YoY from Rs 807.48 million in Q1FY26, but declining by 29.63% QoQ from Rs 1,392.27 million in Q4FY26.
- Net Profit: Net profit for the period was Rs 732.85 million in Q1FY27, reflecting a YoY growth of 21.22% from Rs 604.55 million in Q1FY26 and a QoQ decrease of 29.69% from Rs 1,042.36 million in Q4FY26.
- Total Comprehensive Income: The company recorded Rs 930.23 million in Q1FY27, up 50.00% YoY from Rs 620.70 million in Q1FY26 and down 2.21% QoQ from Rs 951.22 million in Q4FY26.
- Earnings Per Share (EPS): Basic EPS for Q1FY27 was Rs 3.46, compared to Rs 2.90 in Q1FY26 and Rs 4.93 in Q4FY26.
Standalone Financial Highlights:
- Revenue from Operations: Standalone revenue for Q1FY27 was Rs 5,467.29 million, a YoY growth of 13.19% from Rs 4,830.38 million in Q1FY26 and a QoQ decline of 8.01% from Rs 5,943.40 million in Q4FY26.
- Total Income: Standalone total income stood at Rs 5,502.72 million in Q1FY27, up 11.61% YoY from Rs 4,930.44 million in Q1FY26 and down 9.80% QoQ from Rs 6,100.85 million in Q4FY26.
- Profit Before Tax: Standalone PBT was Rs 953.34 million in Q1FY27, increasing by 22.25% YoY from Rs 779.82 million in Q1FY26 and decreasing by 30.34% QoQ from Rs 1,368.51 million in Q4FY26.
- Net Profit: Standalone net profit for the quarter was Rs 713.39 million in Q1FY27, up 22.22% YoY from Rs 583.70 million in Q1FY26 and down 30.42% QoQ from Rs 1,025.32 million in Q4FY26.
- Earnings Per Share (EPS): Basic EPS for the standalone entity was Rs 3.36 in Q1FY27, compared to Rs 2.80 in Q1FY26 and Rs 4.85 in Q4FY26.
Business Highlights:
- Equity Allotment: During Q1FY27, the company allotted 506,782 equity shares of Rs 1 each following the exercise of employee stock options.
- New Labour Codes: The company assessed the impact of the new Labour Codes (effective November 21, 2025), which resulted in a net expense of Rs 80.01 million recognized as an exceptional item in the financial results for the previous year ended March 31, 2026. This included a credit of Rs 2.92 million resulting from a reassessment of remuneration structures in Q4FY26.
Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said: “We are pleased with the progress made during the quarter and the momentum we continue to see across the business. There is a clear evolution in what large pharmaceutical companies are looking for from their outsourcing partners. The expectation is for strong, scientifically led partners who can take greater ownership of integrated discovery and development programs, rather than simply execute individual pieces of work. We believe that the combination of our technology base, scientific talent and culture is a key reason why large pharmaceutical companies are increasingly bringing significant work to Sai through strategic engagements. These engagements will create a healthy and sustained pipeline over multiple years."
Siva Chittor, Chief Financial Officer, Sai Life Sciences, said: “We have begun FY27 on a healthy note, delivering revenue of Rs 554 crore in Q1, up 12% YoY, with growth across both our CRO and CDMO businesses. CRO maintained strong momentum, growing 24% YoY, while our CMC pipeline continues to strengthen with 33 active commercial molecules and 14 late-phase molecules. Coupled with encouraging traction in our FTE-led engagement model, a healthy balance sheet and disciplined capital allocation, we remain confident in executing our long-term growth strategy.”
Stocks Comparison
Table
Chart
Company name |
LTP |
Market cap (Cr) |
Return (1Y %) |
Risk (Std. Dev.) |
PE Ratio |
Financial Year |
|---|---|---|---|---|---|---|
| Sai Life Sciences Ltd | 1,600.50 | 33,993.69 | 78.26 | 0.07 | 94.01 | Mar 2026 |
| Sun Pharmaceutical Industries Ltd | 1,837.30 | 440,829.81 | 13.40 | 0.05 | 36.35 | Mar 2026 |
| Divis Laboratories Ltd | 9,375.00 | 248,876.79 | 54.92 | 0.11 | 85.02 | Mar 2026 |
| Torrent Pharmaceuticals Ltd | 4,840.00 | 184,098.04 | 36.40 | 0.04 | 84.76 | Mar 2026 |
| Zydus Lifesciences Ltd | 1,160.00 | 115,710.44 | 12.21 | 0.07 | 25.04 | Mar 2026 |
| Cipla Ltd | 1,394.50 | 112,655.86 | -10.59 | 0.06 | 33.02 | Mar 2026 |
| Laurus Labs Ltd | 1,954.00 | 105,577.01 | 118.58 | 0.11 | 96.89 | Mar 2026 |
| Aurobindo Pharma Ltd | 1,734.00 | 99,770.53 | 58.26 | 0.04 | 26.90 | Mar 2026 |
| Dr Reddys Laboratories Ltd | 1,185.00 | 98,909.61 | -9.64 | 0.06 | 30.71 | Mar 2026 |
| Lupin Ltd | 2,083.00 | 95,248.48 | 2.55 | 0.04 | 17.67 | Mar 2026 |
| Mankind Pharma Ltd | 2,300.70 | 95,029.28 | -10.49 | 0.06 | 46.30 | Mar 2026 |
| Glenmark Pharmaceuticals Ltd | 2,447.40 | 69,071.67 | 19.83 | 0.06 | 37.36 | Mar 2026 |
| Alkem Laboratories Ltd | 5,466.50 | 65,360.21 | -0.11 | 0.04 | 29.84 | Mar 2026 |
| Biocon Ltd | 385.00 | 62,743.22 | 8.65 | 0.08 | 150.39 | Mar 2026 |
| Abbott India Ltd | 27,270.00 | 57,948.75 | -11.95 | 0.05 | 35.89 | Mar 2026 |
| Anthem Biosciences Ltd | 928.50 | 52,305.97 | 7.40 | 0.09 | 91.36 | Mar 2026 |
| Ipca Laboratories Ltd | 2,009.60 | 50,984.40 | 53.26 | 0.07 | 37.10 | Mar 2026 |
| Gland Pharma Ltd | 2,961.90 | 48,874.56 | 49.07 | - | 43.30 | Mar 2026 |
| Glaxosmithkline Pharmaceuticals Ltd | 2,838.80 | 48,090.98 | 3.53 | 0.08 | 45.23 | Mar 2026 |
| Ajanta Pharma Ltd | 3,563.60 | 44,530.40 | 39.15 | 0.06 | 39.27 | Mar 2026 |
| J B Chemicals & Pharmaceuticals Ltd | 2,408.90 | 38,676.99 | 45.54 | 0.04 | 54.59 | Mar 2026 |
| Emcure Pharmaceuticals Ltd | 2,003.80 | 38,014.22 | 47.88 | 0.06 | 37.53 | Mar 2026 |
| Wockhardt Ltd | 2,086.10 | 33,897.49 | 34.74 | 0.17 | 81.91 | Mar 2026 |
| Neuland Laboratories Ltd | 22,840.00 | 29,303.47 | 41.37 | 0.12 | 58.96 | Mar 2026 |
| Acutaas Chemicals Ltd | 3,440.30 | 28,166.12 | 133.29 | 0.13 | 72.67 | Mar 2026 |
| Piramal Pharma Ltd | 208.16 | 27,713.34 | 2.48 | 0.10 | -88.14 | Mar 2026 |
| Granules India Ltd | 875.50 | 23,881.87 | 60.33 | 0.05 | 36.04 | Mar 2026 |
| Caplin Point Laboratories Ltd | 2,748.60 | 20,892.57 | 17.96 | 0.12 | 30.81 | Mar 2026 |
| Shilpa Medicare Ltd | 1,021.10 | 19,970.86 | 148.65 | 0.19 | 67.16 | Mar 2026 |
| ERIS Lifesciences Ltd | 1,321.30 | 18,311.01 | -19.85 | 0.05 | 27.50 | Mar 2026 |
| Pfizer Ltd | 4,002.40 | 18,310.07 | -23.07 | 0.06 | 24.90 | Mar 2026 |
| OneSource Specialty Pharma Ltd | 1,594.90 | 18,289.18 | -13.11 | 0.15 | -376.29 | Mar 2025 |
| Alivus Life Sciences Ltd | 1,430.80 | 17,566.14 | 52.37 | - | 29.13 | Mar 2026 |
| Jubilant Pharmova Ltd | 1,065.40 | 16,971.82 | -4.10 | 0.07 | 48.37 | Mar 2026 |
| Astrazeneca Pharma India Ltd | 6,751.50 | 16,878.75 | -26.12 | 0.07 | 99.50 | Mar 2026 |
| Cohance Lifesciences Ltd | 438.00 | 16,757.76 | -54.67 | - | 286.31 | Mar 2026 |
| Alembic Pharmaceuticals Ltd | 845.75 | 16,624.33 | -13.53 | 0.07 | 24.11 | Mar 2026 |
| Concord Biotech Ltd | 1,494.40 | 15,633.85 | -8.63 | - | 57.28 | Mar 2026 |
| Natco Pharma Ltd | 813.40 | 14,568.80 | -5.12 | 0.09 | 12.74 | Mar 2026 |
| Marksans Pharma Ltd | 320.15 | 14,508.04 | 78.62 | 0.14 | 27.81 | Mar 2026 |
| Strides Pharma Science Ltd | 1,219.80 | 11,243.23 | 37.79 | 0.07 | 17.72 | Mar 2026 |
| Viyash Scientific Ltd | 249.65 | 10,997.59 | 30.57 | 0.12 | 41.24 | Mar 2026 |
| Blue Jet Healthcare Ltd | 575.25 | 10,888.08 | -17.63 | 0.17 | 46.35 | Mar 2026 |
| Procter & Gamble Health Ltd | 5,503.50 | 9,135.47 | -13.42 | 0.08 | 25.59 | Mar 2026 |
| Aarti Pharmalabs Ltd | 820.40 | 7,439.37 | -10.67 | - | 34.91 | Mar 2026 |
| Sanofi India Ltd | 3,087.40 | 7,110.28 | -38.88 | 0.08 | 21.96 | Dec 2025 |
| Senores Pharmaceuticals Ltd | 1,402.60 | 6,459.48 | 103.50 | 0.10 | 49.48 | Mar 2025 |
| Jeena Sikho Lifecare Ltd | 510.40 | 6,344.31 | -39.09 | 0.11 | 26.81 | Mar 2026 |
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Sep 18, 2026Allotment of 24000 Equity Shares having Face Value of Rs. 1/- as per Companys ESOP Plan
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Sep 17, 2026Voting Results and Scrutinizers Report of 27th Annual General Meeting (AGM) of the Company
Sai Life Sciences Limited - Shareholders meeting
Sep 17, 2026Sai Life Sciences Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results.
Sai Life Sciences Limited - Analysts/Institutional Investor Meet/Con. Call Updates
Sep 04, 2026Sai Life Sciences Limited has informed the Exchange about Schedule of meet
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sep 04, 2026Investors Conference - 18th September 2026
Sai Life Sciences Limited - ESOP/ESOS/ESPS
Sep 01, 2026Sai Life Sciences Limited has informed the Exchange regarding Allotment of 80600 Shares.
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Sep 01, 2026Allotment of 80600 Equity shares having Face Value ?1/- each as per Companys ESOP Plans
Sai Life Sciences Limited - Copy of Newspaper Publication
Aug 26, 2026Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
Announcement under Regulation 30 (LODR)-Newspaper Publication
Aug 26, 2026Newspaper Publication relating to 27th AGM (Post-dispatch Advt.)
Reg. 34 (1) Annual Report.
Aug 25, 2026Integrated Annual Report of Sai Life Sciences Limited for the FY 2025-26
Information Relating To 27Th Annual General Meeting (AGM) And Cut-Off Date For E-Voting.
Aug 24, 2026Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.
Sai Life Sciences Limited - Copy of Newspaper Publication
Aug 24, 2026Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication
| Ex-Date | Purpose | Notes |
|---|---|---|
| 2026-08-06 | Quarterly Results | |
| 2026-05-14 | Audited Results | |
| 2026-02-05 | Quarterly Results | |
| 2025-11-06 | Quarterly Results | |
| 2025-08-07 | Quarterly Results | |
| 2025-05-13 | Audited Results | |
| 2025-02-06 | Quarterly Results |
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
Client name |
Deal Type |
Date |
Action |
Avg. price |
Quantity |
Exchange |
|---|---|---|---|---|---|---|
| Morgan Stanley Asia Singapore Pte | Block | 2026-03-30 |
Purchase |
1,015.40 | 796,916 | NSE |
| Goldman Sachs Bank Europe Se - Odi | Block | 2026-03-30 |
Sell |
1,015.40 | 796,916 | NSE |
| Goldman Sachs Bank Europe Se - Odi | Block | 2025-09-18 |
Purchase |
898.50 | 602,186 | NSE |
| Goldman Sachs (Singapore) Pte - Odi | Block | 2025-09-18 |
Sell |
898.50 | 602,186 | NSE |
| Goldman Sachs Bank Europe Se - Odi | Block | 2025-09-17 |
Purchase |
881.35 | 401,458 | NSE |
| Goldman Sachs (Singapore) Pte - Odi | Block | 2025-09-17 |
Sell |
881.35 | 401,458 | NSE |
| Goldman Sachs Bank Europe Se - Odi | Block | 2025-09-16 |
Purchase |
882.00 | 275,204 | NSE |
| Goldman Sachs (Singapore) Pte - Odi | Block | 2025-09-16 |
Sell |
882.00 | 275,204 | NSE |
| Societe Generale | Bulk | 2025-08-26 |
Purchase |
871.00 | 1,406,922 | NSE |
| Goldman Sachs (Singapore) Pte | Bulk | 2025-08-26 |
Purchase |
871.05 | 1,104,008 | NSE |
| Share India Securities Limited | Bulk | 2025-08-26 |
Purchase |
872.02 | 1,049,879 | NSE |
| Tpg Asia Vii Sf Pte Ltd | Bulk | 2025-08-26 |
Sell |
871.86 | 10,235,611 | NSE |
| Tpg Asia Vii Sf Pte Ltd | Bulk | 2025-08-26 |
Sell |
871.01 | 10,235,611 | NSE |
| Tpg Asia Vii Sf Pte Ltd | Bulk | 2025-08-26 |
Sell |
871.18 | 10,235,611 | NSE |
| Share India Securities Limited | Bulk | 2025-08-26 |
Sell |
872.31 | 1,036,188 | NSE |
| Nippon India Mutual Fund | Bulk | 2025-06-20 |
Purchase |
722.00 | 2,493,075 | BSE |
| Nippon India Mutual Fund | Bulk | 2025-06-20 |
Purchase |
722.00 | 1,520,775 | BSE |
| Max Life Insurance Company Limited | Bulk | 2025-06-20 |
Purchase |
722.00 | 1,385,042 | BSE |
| Aditya Birla Sun Life Mutual Fund | Bulk | 2025-06-20 |
Purchase |
722.00 | 1,385,042 | BSE |
| Invesco Mutual Fund | Bulk | 2025-06-20 |
Purchase |
722.00 | 1,350,416 | BSE |
| Norges Bank On Account Of The Government Pension Fund Global | Bulk | 2025-06-20 |
Purchase |
722.00 | 1,146,814 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Bulk | 2025-06-20 |
Sell |
722.00 | 10,420,720 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Bulk | 2025-06-20 |
Sell |
722.00 | 10,420,719 | BSE |
| Nippon India Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 2,493,075 | BSE |
| Nippon India Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 2,493,074 | BSE |
| Aditya Birla Sun Life Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 1,385,042 | BSE |
| Max Life Insurance Company Limited | Block | 2025-06-20 |
Purchase |
722.00 | 1,385,042 | BSE |
| Aditya Birla Sun Life Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 1,385,041 | BSE |
| Axis Max Life Insurance Limited | Block | 2025-06-20 |
Purchase |
722.00 | 1,385,041 | BSE |
| Invesco Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 1,350,416 | BSE |
| Invesco Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 1,350,415 | BSE |
| Axis Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 1,155,620 | BSE |
| Norges Bank On Account Of The Government Pension Fund Global | Block | 2025-06-20 |
Purchase |
722.00 | 1,146,814 | BSE |
| Societe Generale | Block | 2025-06-20 |
Purchase |
722.00 | 870,593 | BSE |
| Axis Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 571,394 | BSE |
| Hdfc Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 554,017 | BSE |
| Hdfc Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 554,016 | BSE |
| Blackrock Global Emerging Markets Fund Inc | Block | 2025-06-20 |
Purchase |
722.00 | 480,329 | BSE |
| Blackrock Strategic Funds-Blackrock Emerging Markets Equity Strategies Fund | Block | 2025-06-20 |
Purchase |
722.00 | 480,329 | BSE |
| Morgan Stanley Asia Singapore Pte | Block | 2025-06-20 |
Purchase |
722.00 | 312,210 | BSE |
| Bandhan Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 277,008 | BSE |
| Idfc Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 277,008 | BSE |
| Dsp Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 173,130 | BSE |
| Dsp Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 173,130 | BSE |
| Uti Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 152,354 | BSE |
| Mirae Asset Mutual Fund | Block | 2025-06-20 |
Purchase |
722.00 | 152,354 | BSE |
| Ghisallo Master Fund Lp | Block | 2025-06-20 |
Purchase |
722.00 | 144,098 | BSE |
| Pimco Equity Series Pimco Rae Emerging Markets Fund | Block | 2025-06-20 |
Purchase |
722.00 | 139,889 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 2,493,075 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 2,493,074 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,385,042 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,385,042 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,385,041 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,385,041 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,350,416 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,350,415 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,155,620 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 1,146,814 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 870,593 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 571,394 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 554,017 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 554,016 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 480,329 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 480,329 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 312,210 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 277,008 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 277,008 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 173,130 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 173,130 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 152,354 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 152,354 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 144,098 | BSE |
| Tpg Asia Vii Sf Pte Ltd | Block | 2025-06-20 |
Sell |
722.00 | 139,889 | BSE |
| Small Cap World Fund Inc | Bulk | 2025-02-20 |
Purchase |
684.87 | 1,055,329 | NSE |
| Graviton Research Capital Llp | Bulk | 2024-12-19 |
Purchase |
750.87 | 1,133,934 | NSE |
| Sivaramakrishnan Chittor | Bulk | 2024-12-19 |
Sell |
732.00 | 1,500,000 | NSE |
| Graviton Research Capital Llp | Bulk | 2024-12-19 |
Sell |
750.84 | 1,133,934 | NSE |
| Aakraya Research Llp | Bulk | 2024-12-18 |
Purchase |
722.96 | 1,948,320 | NSE |
| Irage Broking Services Llp | Bulk | 2024-12-18 |
Purchase |
703.56 | 1,625,505 | BSE |
| Nippon India Mutual Fund | Bulk | 2024-12-18 |
Purchase |
650.00 | 1,368,500 | NSE |
| Nk Securities Research Private Limited | Bulk | 2024-12-18 |
Purchase |
718.42 | 1,047,755 | NSE |
| Irage Broking Services Llp | Bulk | 2024-12-18 |
Purchase |
734.87 | 412,769 | NSE |
| Aakraya Research Llp | Bulk | 2024-12-18 |
Sell |
723.24 | 1,948,320 | NSE |
| Irage Broking Services Llp | Bulk | 2024-12-18 |
Sell |
703.88 | 1,653,120 | NSE |
| Nk Securities Research Private Limited | Bulk | 2024-12-18 |
Sell |
718.73 | 1,047,755 | NSE |
| Irage Broking Services Llp | Bulk | 2024-12-18 |
Sell |
738.07 | 385,154 | BSE |
Client name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Avg. Price |
Regulation (Insider/SAST) |
Mode |
|---|---|---|---|---|---|---|---|---|
| Invesco Mutual Fund | Other |
Acquisition |
2025-10-30 | 143,820 | 15,270,648 | SAST 29(2) | Market | |
| Tpg Asia Vii Sf Pte Ltd | Other |
Disposal |
2025-09-29 | 30,706,833 | SAST 29(2) | Market | ||
| Invesco Mutual Fund | Other |
Acquisition |
2025-07-24 | 550,000 | 10,941,723 | SAST 29(1) | Market | |
| Tpg Asia Vii Sf Pte Ltd | Other |
Disposal |
2025-07-12 | 20,841,439 | 30,706,833 | SAST 29(2) | Market | |
| Tuneer Ghosh | Designated Person |
Disposal |
2025-02-26 | 71,116 | 503,884 | 713.07 | Insider Trading | Market Sale |
| Tuneer Ghosh | Designated Person |
Disposal |
2025-02-26 | 71,116 | 503,884 | 0.01 | Insider Trading | Market Sale |
| Rajesh V Naik (Revised) | Designated Person |
Disposal |
2025-01-02 | 150,000 | 0 | 730.00 | Insider Trading | Market Sale |
| Supratim Halder (Revised) | Designated Person |
Disposal |
2025-01-02 | 2,000 | 8,000 | 740.69 | Insider Trading | Market Sale |
| Alagappan Subramanian | Designated Person |
Disposal |
2024-12-27 | 2,000 | 4,000 | 717.50 | Insider Trading | Market Sale |
| Sriram Gopalakrishnan (Revised) | Designated Person |
Disposal |
2024-12-26 | 150,000 | 0 | 732.05 | Insider Trading | Market Sale |
| Srinivas Rao Karra (Revised) | Designated Person |
Disposal |
2024-12-26 | 10,000 | 10,000 | 750.00 | Insider Trading | Market Sale |
| Sivaramakrishnan Chittor (Revised) | Designated Person |
Disposal |
2024-12-26 | 1,500,000 | 900,000 | 732.00 | Insider Trading | Market Sale |
| Srikrishna Chopperla (Revised) | Designated Person |
Disposal |
2024-12-26 | 300,000 | 75,000 | 730.00 | Insider Trading | Market Sale |
| Alluri Srinivasa Raju (Revised) | Designated Person |
Disposal |
2024-12-26 | 40,000 | 10,000 | 750.00 | Insider Trading | Market Sale |
| Lakshmipathi G (Revised) | Designated Person |
Disposal |
2024-12-26 | 9,500 | 500 | 670.61 | Insider Trading | Market Sale |
| Bandaru Sreenivasulu (Revised) | Designated Person |
Disposal |
2024-12-26 | 40,000 | 10,000 | 750.15 | Insider Trading | Market Sale |
| Vasanthamurugesh A (Revised) | Designated Person |
Disposal |
2024-12-26 | 300,000 | 75,000 | 730.00 | Insider Trading | Market Sale |
| Dantuluri Venkata Suryanarayana Varma (Revised) | Designated Person |
Disposal |
2024-12-26 | 20,000 | 10,000 | 659.34 | Insider Trading | Market Sale |
| Mahadevan Krishna Prasad (Revised) | Designated Person |
Disposal |
2024-12-26 | 20,000 | 0 | 757.63 | Insider Trading | Market Sale |
| Mahaboobi (Revised) | Designated Person |
Disposal |
2024-12-26 | 9,000 | 1,000 | 730.00 | Insider Trading | Market Sale |
| Runa Karan (Revised) | Designated Person |
Disposal |
2024-12-26 | 25,000 | 25,000 | 725.11 | Insider Trading | Market Sale |
| Damodharan Muniandi (Revised) | Designated Person |
Disposal |
2024-12-26 | 325,000 | 150,000 | 726.92 | Insider Trading | Market Sale |
| Vasanthamurugesh A | Designated Person |
Disposal |
2024-12-26 | 300,000 | 75,000 | 730.00 | Insider Trading | ESOP |
| Dantuluri Venkata Suryanarayana Varma | Designated Person |
Disposal |
2024-12-26 | 20,000 | 10,000 | 659.34 | Insider Trading | ESOP |
| Sivaramakrishnan Chittor | Designated Person |
Disposal |
2024-12-26 | 1,500,000 | 900,000 | 732.00 | Insider Trading | ESOP |
| Runa Karan | Designated Person |
Disposal |
2024-12-26 | 25,000 | 25,000 | 725.11 | Insider Trading | ESOP |
| Srinivas Rao Karra | Designated Person |
Disposal |
2024-12-26 | 10,000 | 10,000 | 750.00 | Insider Trading | ESOP |
| Mahadevan Krishna Prasad | Designated Person |
Disposal |
2024-12-26 | 20,000 | 0 | 757.63 | Insider Trading | ESOP |
| Lakshmipathi G | Designated Person |
Disposal |
2024-12-26 | 9,500 | 500 | 670.61 | Insider Trading | ESOP |
| Alluri Srinivasa Raju | Designated Person |
Disposal |
2024-12-26 | 40,000 | 10,000 | 750.00 | Insider Trading | ESOP |
| Srikrishna Chopperla | Designated Person |
Disposal |
2024-12-26 | 300,000 | 75,000 | 730.00 | Insider Trading | ESOP |
| Sriram Gopalakrishnan | Designated Person |
Disposal |
2024-12-26 | 150,000 | 0 | 732.05 | Insider Trading | ESOP |
| Damodharan Muniandi | Designated Person |
Disposal |
2024-12-26 | 325,000 | 150,000 | 726.92 | Insider Trading | ESOP |
| Mahaboobi | Designated Person |
Disposal |
2024-12-26 | 9,000 | 1,000 | 730.00 | Insider Trading | ESOP |
| Bandaru Sreenivasulu | Designated Person |
Disposal |
2024-12-26 | 40,000 | 10,000 | 750.15 | Insider Trading | ESOP |
About Sai Life Sciences Ltd
Stock PE (TTM)
Promoter Holding
Book Value
ROCE
ROE
Sai Life Sciences Limited was originally incorporated as `Sai Dru Syn Laboratories Limited` as a Public Limited Company, dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. The Company received the Certificate of Commencement of Business from Registrar of Companies, Andhra Pradesh on February 17, 1999. Subsequently, the Company name was changed from `Sai Dru Syn Laboratories Limited` to `Sai Life Sciences Limited` dated December 16, 2003. Thereafter, the name of the Company was changed from `Sai Life Sciences Limited` to `Sai Advantium Pharma Limited` dated August 30, 2006 issued by the Registrar of Companies, Andhra Pradesh. Subsequently, the Company name was changed from `Sai Advantium Pharma Limited` to `Sai Life Sciences Limited` and a fresh Certificate of Incorporation dated May 28, 2012 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. The Company is an innovator-focused contract research, development, and manufacturing organization (CRDMO). The Company provide end-to-end services across the drug discovery, development and manufacturing value chain, for small molecule NCE to global pharmaceutical innovators companies and biotechnology firms. It possess both (a) discovery / contract research and (b) CMC / CDMO capabilities. Through the Scheme of Amalgamation, Prasad Drugs Limited was merged into the Company in 2004. The Company acquired Merrifield Pharma Private Limited in 2006. Later, the Company opened new areas of biology facility in Watertown (Greater Boston, MA) U.S.A. for innovative and creative small-molecule drugs in 2019. It launched Sai Nxt, an initiative to transform the organization into a new generation CDMO in 2020. It further added cellular analysis platforms at its discovery biology facility in Cambridge, Massachusetts, USA. In 2021, the Company opened a new discovery biology facility at Unit II Plant in Hyderabad. In 2022, it opened the first set of new disconvery chemistry labs at Unit III Plant, Hyderabad. In 2023, the Company opened high potency API manufacturing block at Unit IV Bidar Facility. Production Block -11 commenced operations in 2024. The Company raised funds aggregating Rs 3042.6 Crore by issuing 55,421,123 equity shares of face value of Re 1 each, comprising a fresh issue of 17,304,189 equity shares amounting to Rs 950 Cr and 38,116,934 equity shares amounting to Rs 2092.62 Cr in December 2024. In 2025, the Company opened a dedicated facility for Veterinary APIs (Unit VI) in Bidar.
Sai Life Sciences share price as on 21 Sep 2026 is Rs. 1600.5. Over the past 6 months, the Sai Life Sciences share price has increased by 62.3% and in the last one year, it has increased by 78.26%. The 52-week low for Sai Life Sciences share price was Rs. 783.85 and 52-week high was Rs. 1697.
Plot #.DS-7 IKP Knowledge Park, Turkapally (V) Shameerpet Md, Hyderabad, Telangana, 500078
Tel No. +91 40 6815 6000
Email investors:sailife.com
Whole Time Director & CFO
Independent Non Exe. Director
Company Sec. & Compli. Officer
Independent Non Exe. Director
Independent Non Exe. Director
Chairman & Exec. Director
Managing Director & CEO
544306
SAILIFE
INE570L01029
Sep
Sai Life Sciences Ltd FAQs
You can buy Sai Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Sai Life Sciences Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 18, 2026 03:59 PM the closing price of Sai Life Sciences Ltd was Rs.1,600.50.
The latest PE ratio of Sai Life Sciences Ltd as of Sep 18, 2026 03:59 PM is 94.01
The latest PB ratio of Sai Life Sciences Ltd as of Sep 18, 2026 03:59 PM is 13.69
The 52-week high of Sai Life Sciences Ltd share price is Rs. 1,697.00 while the 52-week low is Rs. 783.85
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 18, 2026 03:59 PM, the market cap of Sai Life Sciences Ltd stood at Rs. 33,976.37 Cr.
